Crotalus durissus terrificus snake venom metalloproteinase and serine protease (Cdt SVMP/SVSP)

Crotalus durissus terrificus snake venom metalloproteinases (SVMPs) and serine proteases (SVSPs) are key enzymatic components found in the venom of the South American rattlesnake. SVMPs are zinc-dependent enzymes that degrade basement membrane components and extracellular matrix proteins, leading to localized hemorrhage and systemic inflammatory responses (Boldrini-França et al., 2010). SVSPs, such as gyroxin, primarily target the coagulation cascade, acting as thrombin-like enzymes that cleave fibrinogen or activate other clotting factors, resulting in consumptive coagulopathy (Sano-Martins et al., 2001). While the venom of C. d. terrificus is predominantly characterized by the neurotoxic action of crotoxin, these proteases contribute significantly to the overall pathophysiology of envenomation, including hematological disturbances (Souza et al., 2000). These enzymes are the primary targets for therapeutic neutralization by specific antivenoms produced by immunization of horses with Crotalus venom (Instituto Butantan). Research also explores the use of small-molecule inhibitors like marimastat for SVMPs and nafamostat for SVSPs to augment traditional antivenom therapy (Arias et al., 2017). These inhibitors aim to provide rapid field-based treatment to prevent the progression of systemic damage before hospital-based antivenom administration. Understanding the specific isoforms of these proteases is crucial for developing more effective, broad-spectrum treatments for crotalid envenomation.

Other names

Cdt venom proteasesSouth American rattlesnake venom enzymesCrotalus durissus terrificus metalloproteinasesCrotalus durissus terrificus serine proteasesCrotalysinGyroxinCdt SVMPCdt SVSP

The primary mechanism of action for therapeutic intervention is the neutralization of enzymatic activity. Antivenoms contain specific antibodies that bind to the toxins, preventing their interaction with physiological substrates (Sano-Martins et al., 2001). Small-molecule inhibitors like marimastat act as peptidomimetic competitive inhibitors that bind to the zinc-dependent active site of SVMPs, while serine protease inhibitors like nafamostat block the catalytic triad of SVSPs (Arias et al., 2017).